Although studies on KAT6 inhibition reveal differences, they suggest that KAT6 inhibitors are suitable for patients with ER+ breast cancer, and combining KAT6 inhibitors with ET may achieve enhanced clinical benefits. The gene discussed is ESR1; the disease is breast carcinoma.